Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors, such as palbociclib, are a novel orally administered preventative treatment for CIA due to their ability to pharmacologically induce cell cycle arrest in HFs [35,70,71,72,73,74]. The gene discussed is CDK4; the disease is Hand-foot syndrome.